ESC Professional Premium Access

Treatment of pulmonary arterial hypertension: the old and the new

Event: ESC Congress 2022
Topic: Pulmonary Hypertension
Session type: Moderated ePosters
Date: 28 August 2022
Time: 17:15 - 17:45

Congress Session

5 presentations in this session

Efficacy and dose-response relationship of oral treprostinil in PAH patients on monotherapy or dual background therapy

Speaker: Doctor J. Barbera (Barcelona, ES)
Thumbnail

UNISUS study design: a phase 3 superiority study comparing the efficacy, safety, and tolerability of macitentan 75 mg vs macitentan 10 mg in patients with pulmonary arterial hypertension (PAH)

Speaker: Professor V. McLaughlin (Ann Arbor, US)
Thumbnail

Macitentan for pulmonary arterial hypertension related to repaired congenital heart disease: Real-world UK experience

Speaker: Doctor A. Constantine (London, GB)
Thumbnail

Change in REVEAL Lite 2 and COMPERA 2.0 risk status in patients with pulmonary arterial hypertension initiating oral treprostinil on dual background therapy: a retrospective chart review

Speaker: Doctor M. Sketch (Research Triangle Park, US)
Thumbnail

Human umbilical cord mesenchymal stem cells attenuate experimental pulmonary arterial hypertension

Speaker: Professor H. Dai (Kunming, CN)
Thumbnail

5 speakers from this session

Doctor Joan Albert Barbera

Hospital Clinic, University of Barcelona, Barcelona (Spain)
0 follower

Professor Vallerie McLaughlin

University of Michigan, Ann Arbor (United States of America)
5 presentations
0 follower

Doctor Andrew Constantine

Royal Brompton Hospital, London (United Kingdom of Great Britain & Northern Ireland)
1 follower

Doctor Margaret Sketch

United Therapeutics Corporation, Research Triangle Park (United States of America)
0 follower

Professor Hai-Long Dai

Yan'an Affiliated Hospital of Kunming Medical University, Kunming (China)
0 follower

This platform is supported by

logo Novo Nordisk